Australia markets closed

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.8000-0.0500 (-1.75%)
At close: 04:00PM EDT

Centogene N.V.

Am Strande 7
Rostock 18055
49 381 80113 500

Sector(s):Β Healthcare
Industry:Β Diagnostics & Research
Full-time employees:Β 808

Key executives

NameTitlePayExercisedYear born
Dr. Andrin Oswald M.D., Ph.D.Advisor471.14kN/A1972
Ms. Kim StrattonCEO & Member of Management BoardN/AN/A1962
Mr. Jose Miguel Coego RiosExec. VP of Fin. & Legal and Interim CFON/AN/AN/A
Dr. Patrice P. Denefle Ph.D.Chief Scientific OfficerN/AN/A1960
Ms. Nathalie DasteChief HR OfficerN/AN/A1977
Mr. Florian Vogel Ph.D.Chief Process OfficerN/AN/A1981
Dr. Peter Bauer M.D.Chief Genomic OfficerN/AN/A1970
Dr. Gunter Maximilian Schmid M.D.Chief Commercial Officer of DiagnosticsN/AN/A1967
Mr. Lennart M. StreibelDirector of Corp. ProjectsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

Corporate governance

Centogene N.V.’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.